References
- Rundles RW, Moore JO. Chronic lymphocytic leukemia. Cancer. 1978;42(S2):941–945. doi:10.1002/1097-0142(197808)42:2+<941::AID-CNCR2820420717>3.0.CO;2-1
- Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705. doi:10.1002/ajh.26367
- Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. Am J Hematol. 2019;94(11):1266–1287. doi:10.1002/ajh.25595
- Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer. 2019;125(9):1432–1440. doi:10.1002/cncr.31931
- SRP, SEER 2020 METRICS. [cited 2023 Jan 24]. Available from: https://seer.cancer.gov/about/factsheets/metrics.pdf
- U.S. Census Bureau QuickFacts: United States. [cited 2023 Jan 24]. Available from: https://www.census.gov/quickfacts/fact/table/US/PST045222
- Vardell VA, Ermann DA, Fitzgerald LA, et al. Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. Am J Hematol. 2023;98(7):E172–E174. doi:10.1002/ajh.26937
- Nabhan C, Aschebrook-Kilfoy B, Chiu BC-H, et al. The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive surveillance, epidemiology, and end results analysis in the modern era. Leuk Lymphoma. 2014;55(12):2778–2784. doi:10.3109/10428194.2014.898758
- Barr PM, Owen C, Robak T, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–3450. doi:10.1182/bloodadvances.2021006434